Turnstone Biologics Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sammy J. Farah
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9310 Athena Circle LA Jolla CA United States of America 92037
- IPO Date
- Jul 21, 2023
- CIK
- 0001764974
- Website
- turnstonebio.com
- Similar Companies
- Business
- Turnstone Biologics Corp. (TSBX) is a clinical-stage biotechnology company focused on developing next-generation tumor-infiltrating lymphocyte (TIL) therapies, known as Selected TIL, to treat patients with solid tumors including colorectal cancer, head and neck squamous cell carcinoma, uveal melanoma, breast cancer, and cutaneous melanoma; the company employs a proprietary process to isolate, select, and expand the most potent tumor-reactive T cells from patient tumors for enhanced immunotherapy efficacy beyond first-generation bulk TIL approaches. Programs such as TIDAL-01 and TIDAL-02 advance through multiple Phase 1 clinical trials evaluating this selected TIL technology in high-unmet-need indications, complemented by strategic research into viral immunotherapies and immune modulation. Founded in 2015 and headquartered in San Diego, California, Turnstone operates primarily in the United States with clinical collaborations including Moffitt Cancer Center for TIL therapy development and FDA-cleared IND studies. In October 2024, the company announced a strategic restructuring to prioritize its TIDAL-01 clinical program, reduce staff, and extend its cash runway by three quarters amid preclinical pipeline deprioritization. On June 27, 2025, XOMA Royalty Corporation agreed to acquire Turnstone for $0.34 per share in cash plus a non-transferable contingent value right, with the tender offer commencing by July 11, 2025, board approval, and 25.2% stockholder support; XOMA Royalty completed the acquisition in 2025, integrating Turnstone's assets into its royalty portfolio.
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Turnstone Biologics Corp. (NASDAQ: TSBX)
TSBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Turnstone Biologics Corp. Is Fair to Shareholders
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Turnstone Biologics Shifts Focus To 'High Unmet Medical Need' Cancers, Shares Initial Data From Colorectal Cancer Cell Therapy Study
Why Is Turnstone Biologics (TSBX) Stock Down 38% Today?
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
4 Stocks Under $5 To Buy Now
Turnstone Biologics Corp. Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Turnstone Biologics to Present at the 2024 Bank of America Securities Health Care Conference
Turnstone Biologics Appoints William Waddill to its Board of Directors
Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights
Turnstone Biologics to Participate in Upcoming Investor Conferences
Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.
Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference
Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights
Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting